Express Scripts turns to AbbVie in huge hepatitis C deal

December 22, 2014 3:27 PM

16 0

The nation’s largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a new drug from AbbVie while pulling back on more expensive options from rival drugmakers.

Express Scripts Holding Co. said Monday it will no longer cover Sovaldi and Harvoni from Gilead Sciences Inc. or Johnson & Johnson’s Olysio starting Jan. 1, except under limited circumstances. AbbVie Inc.’s Viekira Pak, approved only Friday, will become the preferred treatment for patients who have ...

Read more

To category page